Recent News

The latest news from the governments, medical industry and top online sources.

EMA consults on virtual control groups to help reduce animal…

EMA’s human medicines committee (CHMP) has issued a draft qualification opinion for a new methodology in preclinical research, which can reduce the overall number of animals (rats) used in specific dose-range finding studies. This method replaces standard (concurrent) animal control groups with virtual control groups. By qualifying this new approach methodology (NAM), the CHMP can accept […]

Laigo Bio completes final close of €17m seed financing round

Laigo Bio has completed the second close of its seed financing round at €5.5m, bringing the total raised to €17m New co-lead investor Biovance Capital and existing co-lead investor Kurma Partners provided the latest investment. The money will be used to further develop Laigo’s Surface Removal Targeting Chimeras (SureTACs) oncology programmes, and to advance its […]

EMA Management Board: highlights of March 2026 meeting

EMA annual report 2025 The Management Board adopted EMA’s annual report for 2025, marking another strong year for medicines regulation in the European Union. EMA delivered 104 positive recommendations for new medicines for human use, including 38 containing a new active substance. The Agency also issued 30 recommendations for new veterinary medicines – the highest number […]

HUTCHMED begins global trial of novel attc therapy hmpl‑a580…

First‑in‑human phase 1/2a study launches in China and the US targeting advanced cancers HUTCHMED has initiated a global phase 1/2a clinical trial of HMPL‑A580, its second antibody‑targeted therapy conjugate, in patients with unresectable, advanced or metastatic solid tumours in China and the US. The first patient received a dose on 4 March 2026. HMPL‑A580 is […]

Recruitment procedure opens for next Executive Director of t…

The vacancy notice for the next EMA Executive Director has been published in the Official Journal of the European Union, marking the beginning of the recruitment process for the most senior role at the Agency. The next Executive Director will take over the position from the current Executive Director, Emer Cooke, whose mandate at the […]

European life sciences coalition launched to boost investmen…

New group aims to address structural barriers holding back Europe’s biotech scale‑up The European Life Sciences Coalition has been launched in Brussels with the aim of strengthening Europe’s life sciences and biotechnology venture capital environment by mobilising greater levels of public and private investment. Created in association with Invest Europe, the coalition brings together leading […]

First treatment for rare thymidine kinase 2 deficiency

EMA has recommended granting a marketing authorisation in the European Union for Kygevvi (doxecitine and doxribtimine) in patients with genetically confirmed thymidine kinase 2 deficiency (TK2d) whose disease started at or before 12 years of age. TK2d is a rare, life-threatening genetic disease that affects fewer than 1 in 1,000,000 people and for which there […]

ErVimmune raises 17m euros in funding to develop cancer vacc…

The vaccine could be created as a ready-to-use product, rather than needing to be personalised ErVimmune, a preclinical biotechnology company focused on the development of cell therapies and cancer vaccines, has announced a total of 17m euros in new funding, allowing it to advance its cancer vaccine candidate. The company’s lead candidate, ErVac01, is a […]

Emer Cooke, EMA’s Executive Director: 2025 achievements in m…

Second, we will intensify our support for innovation for public and animal health. We will further enhance our early development support to enable new medicines to be authorised in the EU as rapidly as possible. Third, we will continue to invest in our staff and build the network of tomorrow. This investment in the European medicines regulatory […]

MRM Health collaborates with Oncode Institute and Netherland…

MRM’s platform could optimise the link between the gut microbiome and cancer outcomes MRM Health, a clinical-stage biopharmaceutical company developing microbiome-based therapeutics for inflammatory diseases and immuno-oncology, has announced its collaboration with Professor Emile Voest, senior group leader at the Netherlands Cancer Institute (NKI) and senior investigator at Oncode Institute. MRM hopes to accelerate the […]